Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

Background Patients with active cancer and venous thromboembolism (VTE) are at high risk
of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is …

Background The safety and efficacy of edoxaban and dalteparin is unclear for several
cancer groups. Methods We evaluated the occurrence of the primary outcome in large …

Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral
anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous …

Direct oral anticoagulants may be effective and safe for treatment of venous
thromboembolism (VTE) in cancer patients, but they have not been compared with low …

Two randomized trials in cancer patients evaluating DOACs have been reported [6, 7].
HOKUSAI Cancer was an open-label, non-inferiority trial that randomized 1050 patients with …

In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite
outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients …

Background Recent guidelines recommend consideration of the use of oral edoxaban or
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …

Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging
due to complications—including bleeding and potential drug–drug interactions with …

The treatment of venous thromboembolism (VTE) in patients with cancer is challenging
because these patients have increased risks of both recurrent VTE and major bleeding …